ArmaGen Technologies Obtains $17,000,000 Series A Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=31581031-edf2-4366-ae6c-fb29dc3e7f79&Preview=1 -
Date
12/3/2012 -
Company Name
ArmaGen Technologies -
Mailing Address
914 Colorado Ave Santa Monica, CA 90401 -
Company Description
ArmaGen provides platform technology solutions to the ‘blood-brain barrier’ problem, and can non-invasively target recombinant proteins, therapeutic monoclonal antibodies, and siRNA to the brain. -
Website
http://www.armagen.com -
Transaction Type
Venture Equity -
Transaction Amount
$17,000,000 -
Transaction Round
Series A -
Proceeds Purposes
The company will use the financing to start clinical trials of its biopharmaceutical candidates. -
M&A Terms
-
Venture Investor
Shire Pharmaceuticals -
Venture Investor
Takeda Ventures -
Venture Investor
Mitsui & Co. -
Venture Investor
Boehringer Ingelheim Venture Fund
